Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 30, 2020 at 8:32 PM.

  1. #1 cafead, Mar 30, 2020 at 8:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,973
    Likes Received:
    3
    via Axsome Therapeutics (NASDAQ:AXSM) on Monday released the data from its phase 3 trial for AXS-05 in patients suffering from treatment-resistant depression (TRD), and it was not quite what the company had hoped for. AXS-05 failed to achieve its primary endpoint in the study, although it did show efficacy in its secondary endpoint.

    article source
     
    Quote

Reply to Thread